Can avatrombopag (Sucoxin) be taken long-term to maintain platelet levels?

Avatrombopag is an oral thrombopoietin (TPO) receptor agonist, which can promote the proliferation and differentiation of bone marrow megakaryocytes by activating the TPO receptor, thereby increasing platelet production. Mainly used for patients with chronic liver disease-related thrombocytopenia (CLD) and idiopathic thrombocytopenic purpura (ITP). The drug can be administered orally, has a rapid onset of action, and is well tolerated, so it is used clinically to increase platelet levels to reduce the risk of bleeding or to provide safe platelet conditions for surgery.

In clinical practice, avatrombopag can be used to maintain platelet levels in the long term, especially in ITP patients. Multiple studies have shown that continuous oral administration of avatrombopag can maintain platelet stability for months to years, significantly reduce spontaneous bleeding events, and improve quality of life. The key to long-term use is individualized dose adjustment: gradually adjust the daily dose based on platelet monitoring results to maintain the target platelet range and avoid too high or too low platelets.

Although avatrombopag is well tolerated, potential risks should be noted with long-term use. Common adverse reactions include headache, fatigue, diarrhea, or high platelet levels. Long-term oral administration requires regular monitoring of platelet count and liver function, as well as attention to the risk of thrombosis. If the platelet level continues to be higher than the safe upper limit, the dose needs to be reduced in time or the medication should be temporarily stopped to ensure medication safety.

In long-term platelet maintenance therapy, avatrombopag provides patients with a convenient oral regimen with stable efficacy. Doctors should conduct individualized management based on changes in condition, platelet levels, and comorbid diseases, and combine it with other treatments (such as immunosuppressants or surgical intervention) when necessary. Overall, avatrombopag can be used as an effective drug for long-term platelet maintenance, but strict follow-up and dynamic dose adjustment are required to ensure a balance between safety and efficacy.

Reference materials:https://www.drugs.com/